Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$55.96 USD

55.96
1,905,316

-0.38 (-0.67%)

Updated Aug 7, 2025 03:59 PM ET

After-Market: $56.13 +0.17 (0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $46.68, moving -1.12% from the previous trading session.

Zacks Equity Research

Vertex (VRTX) to Start Clinical Study on mRNA-based CF Therapy

by Zacks Equity Research

Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks.

Zacks Equity Research

Why Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 2.61% and 97.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.

Zacks Equity Research

Earnings Preview: Exact Sciences (EXAS) Q3 Earnings Expected to Decline

by Zacks Equity Research

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

Zacks Equity Research

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $50.84, marking a -0.88% move from the previous day.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $58.06, marking a -0.77% move from the previous day.

Zacks Equity Research

Here's Why You Should Invest in Vertex (VRTX) Stock Now

by Zacks Equity Research

Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.

Zacks Equity Research

The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

by Zacks Equity Research

CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.

Indrajit Bandyopadhyay headshot

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

by Indrajit Bandyopadhyay

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.

Zacks Equity Research

bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line

by Zacks Equity Research

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $65.35, marking a +1.33% move from the previous day.

Zacks Equity Research

Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy

by Zacks Equity Research

Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $70.13, moving +1.9% from the previous trading session.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $66.27 in the latest trading session, marking a +1.94% move from the prior day.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Down 16.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth

by Zacks Equity Research

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

Zacks Equity Research

Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?

by Zacks Equity Research

Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.

Zacks Equity Research

A Comprehensive Guide to Genomic ETFs

by Zacks Equity Research

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.